FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2594449730> ?p ?o ?g. }

• W2594449730 abstract "Abstract Abstract 5041 Background: Novel biological agents, particularly bortezomib (B) and the immunomodulatory agents thalidomide (T) and lenalidomide (L), have improved the response rates and the survival in multiple myeloma (MM). However, patients refractory to, or progressing after, treatment with one or more new agents have a very poor prognosis. Alkylating agents are often avoided in the initial management of MM patients who are eligible for autologous hematopoietic stem cell (HSC) transplantation due to concerns for impairment of HSC mobilization. We hypothesized that high doses of cyclophosphamide (HiCy) administered without HSC support may be an effective and safe treatment to rescue patients with relapsed or refractory MM previously treated with novel biological agents. Methods: We performed a retrospective single institution review of all recent patients receiving high dose cyclophosphamide (3000mg/m2) after failure of one or more new biological agents. Data extracted included patient demographics, disease characteristics, treatment history, toxicity, response, and survival data. This study received institutional review board approval. Results: Between 03/2009 and 06/2010, 11 patients were treated with cyclophosphamide 3,000mg/m2 for relapsed or refractory MM. Supportive care included administration of mesna to prevent hemorrhagic cystitis and PEG-filgrastim to minimize the duration and depth of neutropenia. All patients received antibiotic prophylaxis with ciprofloxacin, acyclovir, and fluconazole. The median age of patients was 52 years (range 26–73). Among these, 7 patients (64%) had stage 2 (international staging system), and 4 patients (36%) had stage 3 disease. Metaphase cytogenetics and/or fluorescence in situ hybridization (FISH) was available for 10 patients. In all but one patient, MM cells had FISH abnormalities. Cytogenetic subgroups included five cases with complex karyotype, 6 cases with a deletion of chromosome 13, 3 cases with abnormalities involving 17p, 2 cases with t(11;14), 2 hyperdiploid cases, and 1 case with t(14;16). The median number of prior treatments was 3 (range 1–6) with two patients previously receiving autologous HSC transplantation. All patients were refractory to the last therapeutic regimen and had failed to respond or were refractory to a regimen containing B. Seven patients had also previously received an immunomodulatory agent (2 patients received T and 6 patients received L). At the time of treatment 5 patients had plasma cell leukemia and 5 patients had renal failure (including 2 patients on dialysis). All patients developed grade 4 neutropenia, and 9 patients developed thrombocytopenia requiring transfusion support. Six patients (55%) developed fever and neutropenia requiring intravenous antibiotics, and one patient (9%) had documented bacteremia. One patient died from sepsis 7 weeks after cyclophosphamide treatment. Median follow up was 13.4 weeks (range 4.4–69.7) from HiCy administration. Overall, 7 patients had a partial response or better (64%), including 3 patients with a very good partial response (27%). Four of the 7 responding patients subsequently underwent autologous (3) or allogeneic (1) HSC transplantation. Median overall survival was not reached, and the estimated one year survival was 52.5% (+/− 20.4%). Conclusion: High-dose cyclophosphamide can be an effective salvage therapy for young, high-risk MM patients refractory to new biological agents. HiCy is associated with significant toxicity, and careful patient selection is necessary. Disclosures: No relevant conflicts of interest to declare." @default.
• W2594449730 created "2017-03-16" @default.
• W2594449730 creator A5005850190 @default.
• W2594449730 creator A5015493242 @default.
• W2594449730 creator A5057989105 @default.
• W2594449730 date "2010-11-19" @default.
• W2594449730 modified "2023-09-27" @default.
• W2594449730 title "High-Dose Cyclophosphamide Is An Effective Salvage Therapy for High-Risk Multiple Myeloma Refractory to New Biological Agents" @default.
• W2594449730 doi "https://doi.org/10.1182/blood.v116.21.5041.5041" @default.
• W2594449730 hasPublicationYear "2010" @default.
• W2594449730 type Work @default.
• W2594449730 sameAs 2594449730 @default.
• W2594449730 citedByCount "0" @default.
• W2594449730 crossrefType "journal-article" @default.
• W2594449730 hasAuthorship W2594449730A5005850190 @default.
• W2594449730 hasAuthorship W2594449730A5015493242 @default.
• W2594449730 hasAuthorship W2594449730A5057989105 @default.
• W2594449730 hasConcept C126322002 @default.
• W2594449730 hasConcept C141071460 @default.
• W2594449730 hasConcept C143998085 @default.
• W2594449730 hasConcept C2776063141 @default.
• W2594449730 hasConcept C2776364478 @default.
• W2594449730 hasConcept C2776694085 @default.
• W2594449730 hasConcept C2776755627 @default.
• W2594449730 hasConcept C2777063308 @default.
• W2594449730 hasConcept C2777408962 @default.
• W2594449730 hasConcept C2777478702 @default.
• W2594449730 hasConcept C2780775027 @default.
• W2594449730 hasConcept C2911091166 @default.
• W2594449730 hasConcept C71924100 @default.
• W2594449730 hasConceptScore W2594449730C126322002 @default.
• W2594449730 hasConceptScore W2594449730C141071460 @default.
• W2594449730 hasConceptScore W2594449730C143998085 @default.
• W2594449730 hasConceptScore W2594449730C2776063141 @default.
• W2594449730 hasConceptScore W2594449730C2776364478 @default.
• W2594449730 hasConceptScore W2594449730C2776694085 @default.
• W2594449730 hasConceptScore W2594449730C2776755627 @default.
• W2594449730 hasConceptScore W2594449730C2777063308 @default.
• W2594449730 hasConceptScore W2594449730C2777408962 @default.
• W2594449730 hasConceptScore W2594449730C2777478702 @default.
• W2594449730 hasConceptScore W2594449730C2780775027 @default.
• W2594449730 hasConceptScore W2594449730C2911091166 @default.
• W2594449730 hasConceptScore W2594449730C71924100 @default.
• W2594449730 hasLocation W25944497301 @default.
• W2594449730 hasOpenAccess W2594449730 @default.
• W2594449730 hasPrimaryLocation W25944497301 @default.
• W2594449730 hasRelatedWork W1616474014 @default.
• W2594449730 hasRelatedWork W2067103362 @default.
• W2594449730 hasRelatedWork W2178873292 @default.
• W2594449730 hasRelatedWork W2325292071 @default.
• W2594449730 hasRelatedWork W2558932821 @default.
• W2594449730 hasRelatedWork W2561878048 @default.
• W2594449730 hasRelatedWork W2566033835 @default.
• W2594449730 hasRelatedWork W2570224382 @default.
• W2594449730 hasRelatedWork W2572092593 @default.
• W2594449730 hasRelatedWork W2576334191 @default.
• W2594449730 hasRelatedWork W2580091056 @default.
• W2594449730 hasRelatedWork W2588256988 @default.
• W2594449730 hasRelatedWork W2589503393 @default.
• W2594449730 hasRelatedWork W2590613491 @default.
• W2594449730 hasRelatedWork W2591001182 @default.
• W2594449730 hasRelatedWork W2911669613 @default.
• W2594449730 hasRelatedWork W2979743524 @default.
• W2594449730 hasRelatedWork W2994190077 @default.
• W2594449730 hasRelatedWork W3003909887 @default.
• W2594449730 hasRelatedWork W2008004590 @default.
• W2594449730 isParatext "false" @default.
• W2594449730 isRetracted "false" @default.
• W2594449730 magId "2594449730" @default.
• W2594449730 workType "article" @default.